Why BASF's Return to #1 Masks a 47% Profit Collapse Across the ICIS Top 100
Why BASF's Return to #1 Masks a 47% Profit Collapse Across the ICIS Top 100
On 14 September 2026, ICIS released its annual Top 100 Chemical Companies ranking. BASF reclaimed the top position with $70.0 billion in 2025 sales, ahead of Sinopec ($66.3 billion), ExxonMobil ($53.4 billion), PetroChina ($42.1 billion) and Dow ($40.0 billion). The leaderboard reshuffle makes for a clean headline. It is not the main story. Across the full Top 100, operating profits fell 47.3% in 2025 on sales that declined only 4.6%. Net profits collapsed 81.9%. Those figures confirm what many producers already felt on the ground: 2025 was a cycle-bottom year for earnings, even among the industry’s largest and most diversified players.
ICIS itself frames 2026 as a potential year of “meaningful margin recovery,” supported by supply shortages linked to the Middle East conflict—shortages of both finished chemicals and the feedstocks used to make them. Whether that recovery materialises will be tested against actual third- and fourth-quarter 2026 results. Until then, the Top 100 data stand as a clear record of how severely profitability was compressed while volumes and sales held up far better than earnings.
The Leaderboard versus the P&L
Sales rankings reward scale. BASF’s return to #1 reflects the breadth of its portfolio and the relative resilience of its reported top line in dollar terms. Sinopec’s close second and the presence of four Chinese companies in the Top 10 underline the continued shift in global capacity and output toward Asia. ExxonMobil, PetroChina and Dow complete a top five that mixes integrated oil-chemical majors with pure-play chemical producers.
None of that ranking, however, captures the earnings destruction of 2025. A 4.6% sales decline is material but manageable. A 47.3% drop in operating profit and an 81.9% collapse in net profit are of a different order. They indicate that price and margin compression—driven by petrochemical overcapacity, weak demand in housing, automotive and durable goods, and elevated costs in several regions—overwhelmed any benefit from modest volume or mix effects. The industry did not merely grow more slowly; it became dramatically less profitable at the operating and net levels.
Cycle Bottom and the China Capacity Factor
ICIS Global Editor Joseph Chang described 2025 as likely the cycle bottom for earnings, with petrochemical overcapacity led by Chinese expansions combining with soft end-market demand to depress prices and margins throughout the year. That diagnosis aligns with the aggregate Top 100 numbers. When capacity additions outrun demand for an extended period, the resulting oversupply shows up first in margins and only later, and less severely, in headline sales—especially for diversified companies that can still move volume in specialties, agricultural chemicals or other less cyclical segments.
Chinese producers’ heavy representation in the upper ranks is consistent with their role as the most active capacity expanders. Scale has risen; returns have not. The same dynamic has pressured European and North American producers that face higher energy and regulatory costs while competing in globally traded commodity chains.
What the Profit Collapse Means for Strategy
A near-halving of operating profit and an 80%-plus drop in net profit across the Top 100 force prioritisation. Companies have already responded with portfolio reviews, cost programmes, selective capacity closures and, in some cases, delayed or cancelled growth projects. Capital expenditure discipline has tightened. The premium on feedstock advantage, energy efficiency and exposure to more resilient end markets has increased. Specialty and “defensible” businesses that can sustain margins through the cycle have attracted relatively more strategic attention and, in the M&A market, more capital.
For ESG and performance reporting, the 2025 results also complicate simple narratives of continuous improvement. Absolute emissions may fall when plants run at lower rates, yet the emissions intensity of the remaining output and the financial capacity to fund decarbonisation both deteriorate when profits collapse. Investors and customers looking for credible transition plans must now assess those plans against a much weaker earnings base.
The 2026 Recovery Hypothesis
ICIS’s accompanying commentary points to 2026 as a year of meaningful margin recovery, buoyed by Middle East-related supply shortages of chemicals and feedstocks. Geopolitical disruption can tighten balances and lift prices even when underlying demand remains only moderate. Some producers have already reported sequential improvement in certain chains. The critical test is whether those gains are broad enough, and durable enough, to reverse a 47% operating-profit decline at the Top 100 level.
Third- and fourth-quarter 2026 results will provide the first clear evidence. A genuine recovery would show up as sustained margin expansion across multiple regions and product families, not only in the chains most directly affected by logistics constraints. A partial or fleeting rebound would leave the industry still repairing balance sheets and still cautious on new capacity.
Implications for Rankings and Relative Position
BASF’s return to the sales #1 slot is real and newsworthy. It does not restore the profitability conditions of earlier cycle peaks. Sinopec and other large Asian producers have closed the sales gap and, in some years, overtaken Western peers on top-line measures. The deeper question for European and North American majors is whether they can convert any 2026 margin recovery into structurally higher returns, or whether the combination of high regional costs and global overcapacity will keep earnings subdued even when volumes stabilise.
Customers and suppliers reading the Top 100 should look past the ordinal ranking. The companies that enter 2027 with repaired margins, clearer portfolios and credible cost positions will be better able to invest, to honour long-term supply commitments and to fund the next phase of decarbonisation. Those that merely regained a sales ranking while remaining deep in the earnings trough will face continued strategic pressure.
Outlook
The ICIS Top 100 for 2025, published in September 2026, delivers two messages at once. The first is a familiar leaderboard story: BASF is again the world’s largest chemical company by sales, with Sinopec close behind and Chinese producers well represented in the top tier. The second, and more important, is a balance-sheet and P&L story: operating profits across the Top 100 fell 47.3% and net profits fell 81.9% on only a mid-single-digit sales decline. That is the signature of a cycle bottom. Whether 2026 delivers the “meaningful margin recovery” that ICIS anticipates will depend on the durability of Middle East-related supply constraints and on the strength of underlying demand. Until the full-year 2026 numbers are in, the 47% profit collapse remains the clearest takeaway from the latest ranking—and the clearest warning that scale alone no longer guarantees returns in the global chemical industry.
Sources
Polyoxyethylene Lauryl Ether - Taiwan
Found this useful?
